Surveillance programmes and antibiotic resistance: Worldwide and regional monitoring of antibiotic resistance trends

Handbook of Experimental Pharmacology

Volumn 211, Issue , 2012, Pages 31-43

  Hawser, Stephen ^a  

^a International Health Management Associates Europe Sàrl   (Switzerland)

Author keywords

Antibiotic consumption; Global health; Government; Industry; Institutions; Monitoring; Resistance; Surveillance

Indexed keywords

AMINOGLYCOSIDE DERIVATIVE; AMOXICILLIN; AMPICILLIN; ANTIBIOTIC AGENT; CARBAPENEM; CEFOTAXIME; CEFOXITIN; CEFTIOFUR; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLAVULANIC ACID; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; MACROLIDE; NALIDIXIC ACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COLONIZATION; BACTERIUM ISOLATE; BIOINFORMATICS; CAMPYLOBACTER; DRUG INDUSTRY; DRUG MONITORING; DRUG SENSITIVITY; DRUG SURVEILLANCE PROGRAM; DRUG USE; ESCHERICHIA COLI; GEOGRAPHIC DISTRIBUTION; HUMAN; INFECTION CONTROL; INTERNET; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NEWBORN SEPSIS; NONHUMAN; ONLINE ANALYSIS; PNEUMOCOCCAL INFECTION; POLITICAL PARTICIPATION; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; Q FEVER; SALMONELLA; SHIGELLA; TREND STUDY; URINARY TRACT INFECTION; VANCOMYCIN RESISTANT ENTEROCOCCUS; BACTERIUM; DRUG EFFECT; REVIEW;

BACTERIA; DRUG INDUSTRY; DRUG RESISTANCE, MICROBIAL;

EID: 84870226311     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-642-28951-4_3     Document Type: Article

References (50)

1. Andrade S, Sader HS, Barth A (2008) Antimicrobial susceptibility of Gram-negative bacilli isolated in Brazilian hospitals participating in the SENTRY Program (2003-2008). Braz J Infect Dis 12:3-9
2. Ang JY, Ezike E, Asmar BL (2004) Antibacterial resistance. Indian J Pediatr 71:229-239 (Pubitemid 38436961)
3. Australian Government, Department of Health and Ageing (2009) Quarterly report. Comm Dis Intell 33:1-86
4. Barbosa TM, Levy SB (2000) The impact of antibiotic use on resistance development and persistence. Drug Resist Updat 3:303-311
5. Biedenbach DJ, Moet GJ, Jones RN (2004) Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002) Diagn Micro. Infect Dis 50:59-69 (Pubitemid 39360263)
6. Castanheira M, Deshpande LM, Bell JM et al (2010) Early dissemination of NDM-1 and OXA-181-producing Enterobacteriaceae in Indian Hospitals: Report from the SENTRY Antimicrobial Surveillance Program (2006-2007). Antimicrob Agents Chemother. doi:10.1128/ AAC.01497-10
7. Centers for Disease Control and Prevention (2009a) Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group A Streptococcus, 2009
8. Centers for Disease Control and Prevention (2009b) Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Neisseria meningiditis, 2009
9. Centers for Disease Control and Prevention (2009c) Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Haemophilus influenzae, 2009
10. Centers for Disease Control and Prevention (2009d) Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Methicillin-Resistant Staphylococcus aureus, 2008
11. Centers for Disease Control and Prevention (2010) National Antimicrobial Resistance Monitoring System for Enteric Bacteria (NARMS): Human Isolates Final Report, 2008. US Department of Health and Human Services, CDC, Atlanta, Georgia
12. Cizman M (2003) The use and resistance to antibiotics in the community. Int J Antimicrob Agents 21:297-307 (Pubitemid 36397961)
13. DANMAP (2009) DANMAP 2009-Use of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from food animals, foods and humans in Denmark. ISSN 1600-2032
14. Darabi A, Hocquet D, Dowzicky MJ (2010) Antimicrobial activity against Streptococcus pneumoniae and Haemophilus influenzae collected globally between 2004 and 2008 as part of the Tigecycline Evaluation and Surveillance Trial. Diagn Microbiol Infect Dis 67:78-86
15. De Man P, Verhoeven BA, Verbrugh HA et al (2000) An antibiotic policy to prevent emergence of resistant bacilli. Lancet 355:973-978 (Pubitemid 30148263)
16. European Centre for Disease Prevention and Control (2010) Antimicrobial resistance surveillance in Europe 2009. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). ECDC, Stockholm
17. Farrell DJ, Felmingham D, Shackcloth J et al (2008) Non-susceptibility trends and serotype distributions among Streptococcus pneumoniae from community-acquired respiratory tract infections and bacteremias in the UK and Ireland, 1999 to 2007. J Antimicrob Chemother 62 (Suppl 2):ii87-ii95
18. Felmingham D, Grunenburg RN, The Alexander Project Group (2000) The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. J Antimicrob Chemother 45:191-203 (Pubitemid 30095190)
19. Frimodt-Moller N, Hammerum AM, Hessler JHR et al (2007) Global development of resistance. Dan Med Bull 54:160-162 (Pubitemid 46845737)
20. Gales AC, Sader HS, Ribeiro J et al (2009) Antimicrobial susceptibility of Gram-positive bacteria isolated in Brazilian hospitals participating in the SENTRY program (2005-2008). Braz J Infect Dis 13:90-98
21. Garcia-Rey C, Martin-Herrero JE, Baquero F (2006) Antibiotic consumption and generation of resistance in Streptococcus pneumoniae: the paradoxical impact of quinolones in a complex selective landscape. Clin Micro Infect 12(Suppl 3):55-66
22. Goossens H, Ferech M, Vander Stichele R et al (2005) Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 365:579-587 (Pubitemid 40247914)
23. Government of Canada (2010) Canadian Integrated Program for Antimicrobial Resistance Surveillance (CIPARS) 2007. Public Health Agency of Canada
24. Guillemot D, Carbon C, Balkau B et al (1998) Low dosage and long treatment duration of beta-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumonaie. JAMA 279:365-370 (Pubitemid 28133865)
25. Hawser SP (2010) Activity of tigecycline and comparators against recent clinical isolates of Finegoldia magna from Europe. Eur J Clin Microbiol Infect Dis 29:1011-1013
26. Hawser SP, Bouchillon SK, Hoban DJ et al (2009) Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007. Antimicrob Agents Chemother 53:3280-3284
27. Hawser SP, Bouchillon SK, Hoban DJ et al (2010a) Epidemiologic trends, occurrence of extended-spectrum beta-lactamase production, and performance of ertapenem and comparators in patients with intra-abdominal infections: analysis of global trend data from 2002 to 2007 from the SMART study. Surg Infect 11:371-378
28. Hawser SP, Bouchillon SK, Hoban DJ et al (2010b) Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum beta-lactamases in community- and hospital-associated intra-abdominal infections in Europe - Results of the 2008 SMART Study. Antimicrob Agents Chemother 54:3043-3046
29. Hawser SP, Hackel M, Person MB et al (2010c) In vitro activity of tigecycline against carbapenemase-producing Acinetobacter baumannii. Int J Antimicrob Agents 36:289-290
30. Hawser SP, Hackel M, Hoban DJ (2010d) Antibiotic susceptibility profiles of European Bacteroides fragilis with reduced carbapenem susceptibility. J Antimicrob Chemother 65:803-804
31. Hoban DJ, Bouchillon SK, Hawser SP et al (2010) Trends in the frequency of multiple drug-resistant Enterobacteriaceae and their susceptibility to ertapenem, imipenem, and other antimicrobial agents: data from the Study for Monitoring Antimicrobial Resistance Trends 2002 to 2007. Diag Microbiol Infect Dis 66:78-86
32. Hope R, Livermore DM, Brick G et al (2008) Non-susceptibility trends among staphylococci from bacteraemias in the UK and Ireland, 2001-2006. J Antimicrob Chemother 62(Suppl 2):ii65-ii74
33. Hsueh PR, Badal RE, Hawser SP et al (2010) Asia-Pacific SMART Group. Epidemiology and antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region: 2008 results from SMART. Int J Antimicrob Agents 36:408-414
34. Jones RN (1996) The emergent needs for basic research, education and surveillance of antimicrobial resistance. Problems facing the report from the American Society for Microbiology Task Force on Antibiotic Resistance. Diag Micro Infect Dis 25:153-161 (Pubitemid 26392166)
35. Jones RN (1999) Beta-lactam resistance surveillance in the Asia-Western Pacific region. Diag Micro Infect Dis 35:333-338 (Pubitemid 30053056)
36. Levy SB (1992) The antibiotic paradox. Plenum, New York
37. Livermore DM, Hope R, Brick G et al (2008a) Non-susceptibility trends among Pseudomonas aeruginosa and other non-fermentative Gram-negative bacteria from bacteraemias in the UK and Ireland, 2001-2006. J Antimicrob Chemother 62(Suppl 2):ii55-ii63
38. Livermore DM, Hope R, Brick G et al (2008b) Non-susceptibility trends among Enterobac-teriaceae from bacteraemias in the UK and Ireland, 2001-2006. J Antimicrob Chemother 62 (Suppl 2):ii41-ii54
39. Morrissey I, Maher K, Williams L et al (2008) Non-susceptibility trends amonh Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections in the UK and Ireland, 1999-2007. J Antimicrob Chemother 62(suppl 2):ii97-ii103
40. Myrianthefs PM, Kalafati M, Samara I et al (2004) Nosocomial pneumonia. Crit Care Nurs Q 27:241-257 (Pubitemid 38955373)
41. Nagy E, Dowzicky MJ (2010) In vitro activity of tigecycline and comparators against a European compilation of anaerobes collected as part of the Tigecycline Evaluation and Surveillance Trial (TEST). Scand J Infect Dis 42:33-38
42. Sader HS, Jones RN, Gales AC et al (2004) SENTRY antimicrobial surveillance program report: Latin America and Brazilian results for 1997 through 2001. Braz J Infect Dis 8:25-79
43. Sahm DF, Marsilio MK, Piazza G (1999) Antimicrobial resistance in key bloodstream bacterial isolates: electronic surveillance with the Surveillance Network Database-USA. Clin Infect Dis 29:259-263 (Pubitemid 29380180)
44. Skalet AH, Cevallos V, Ayele B et al (2010) Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: A cluster-randomized clinical trial. PLoS Med 7:1-9
45. Standing Medical Advisory Committee Sub-Group on Antimicrobial Resistance (1998) The path of least resistance. Department of Health, London
46. SWEDRES (2009) A report on Swedish Antimicrobial Utilisation and Resistance in Human Medicine. Swedish Strategic Programme against Antibiotic Resistance (STRAMA), Stockholm
47. Tresoldi das Neves M, Pinto de Lorenzo ME, Almeida RAMB et al (2010) Antimicrobial use and incidence of multidrug-resistant Pseudomonas aeruginosa in a teaching hospital: an ecological approach. Rev Soc Brasil Med Trop 43:629-632
48. Vandepitte J, El-Nageh M, Tikhomirov E et al (1996) Guidelines for antimicrobial resistance surveillance; WHO Regional Publications Eastern Mediterranean Series 15. WHO Regional Office for the Eastern Mediterranean, Alexandria
49. Wang YF, Dowzicky MJ (2010) In vitro activity of tigecycline and comparators on Acinetobacter spp. isolates collected from patients with bacteremia and MIC change during the Tigecycline Evaluation and Surveillance Trial, 2004 to 2008. Diagn Microbiol Infect Dis 68:73-79
50. Zhang R, Eggleston K, Rotimi V et al (2006) Antibiotic resistance as a global threat: evidence from China, Kuwait and the United States. Global Health 2:6